Kpongbo Etienne
Angora, Matenin Ouattara, Maurine Aline N’guiachi, Salifou Koné,
N’drin Effoh, Vincent Djohan, Hervé Eby Menan, and Adèle Kacou N’douba, from the institute of the
Côte d’Ivoire. Wrote a research paper about, Vulvovaginal Candidiasis in
Pregnant Women: Antifungal Susceptibility Insights. Entitle, Vulvovaginal
candidiasis and antifungal susceptibility patterns among pregnant women at the
university hospital of Angré, Abidjan, Côte d’Ivoire. This research paper
published by the International journal of Microbiology and Mycology | IJMM.an open access scholarly research journal on Microbiology. under the
affiliation of the International Network For Natural Sciences| INNSpub. an
open access multidisciplinary research journal publisher.
Abstract
Vulvovaginal candidiasis is a frequent reason for consultation in gynecology. Few studies have been conducted in pregnant women, even though they may be asymptomatic. This study aimed to determine the epidemiological profile of vulvovaginal and antifungal susceptibility patterns among pregnant women at the university teaching hospital of Angré in Abidjan. This cross-sectional study was carried out in the gynecology-obstetrics department of the Angré University Hospital from June to October 2024. Swabs were taken from Pregnant women for mycological analyses. Each sample was examined directly and cultured at 37°C on Sabouraud-Chloramphenicol medium. Candida yeasts were identified using Chromagar Candida medium or Vitek 2. Antifungal susceptibility was determined using the agar diffusion method with discs. Of total of 402 women included, 70 were positive on culture, representing an overall vaginal candidiasis carriage rate of 19.2%. The yeast species identified were Candida albicans (48.1%), Candida krusei (27.8%), Candida tropicalis (12.7%), and Candida glabrata (11.4%). Symptoms such as vaginal discharge, vulvar pruritus, and dyspareunia were statistically linked to Candida carriage (p<0.05). Non-albicans species showed low sensitivity to antifungal agents. Candida krusei was only 68% susceptible to amphotericin B and econazole while Candida tropicalis had low susceptibility. This study showed a relatively high frequency of Candida yeasts in pregnant women. The emergence of non- albicans with less susceptibility to the antifungal drugs highlights the importance of systematically screening pregnant women to better manage vulvovaginal candidiasis.
Introduction
Vulvovaginal
candidiasis is a common reason for gynecological consultations and ranks second
after bacterial vaginosis (Sobel, 2007; Konaté et al., 2014). It is estimated
that 75% of women experience at least one episode of candidiasis during their
lifetime. Among these women, some will have several episodes and around 5 to 8%
will develop recurrent vulvovaginal candidiasis (VVC), characterized by at
least four confirmed episodes in a year (Achkar and Fries, 2010).
Certain risk factors
for VVC are related to sexual activity, recent antibiotic use,
immunosuppression attributable to conditions such as poorly controlled HIV
infection or diabetes, and pregnancy (Benchellal et al., 2011; Roy et al.,
2024). All of these factors contribute to an imbalance in the vaginal flora and
the onset of clinical and biological symptoms. Pregnancy is the leading factor
promoting CVV due to the hormonal changes observed (Ogouyèmi-Hounto et al.,
2014; Blomberg et al., 2023). Candida species are part of the normal flora of
the genital tract. In healthy asymptomatic non-pregnant women, these yeasts
have been found in 20–30% (Achkar and Fries, 2010; Ghaddar et al., 2020). This
situation only poses a danger to the fetus and newborn when the manifestations
occur in a context of prematurity or when the prognosis may be lifethreatening
(Hong et al., 2014; Duarte et al., 2024). When vaginal candidiasis is not
asymptomatic, it can lead to vulvar pruritus and characteristic vaginal
discharge. These symptoms may be associated with dysuria, dyspareunia, vaginal
dryness, or vulvar burning (Gai et al., 2023).
Untreated, vaginal
candidiasis can lead to chorioamnionitis with subsequent miscarriage and
prematurity in pregnant women, or congenital infection of inflammatory disease
in newborns and pelvic inflammatory disease in infertile women (Ahmad and Khan,
2009; Gedefie et al., 2025).
Vulvovaginal
candidiasis is most often caused by the overabundance of an opportunistic
pathogenic yeast, Candida albicans (approximately 90%), which is a common
member of the vaginal flora (Hussen et al., 2024). Moreover, the emergence of
Candida species isolated from clinical samples, indicated that nonalbicans
species were considered emerging fungal pathogens in pregnant women (Hussen et
al., 2024; Gedefie et al., 2025). These yeasts are commensal species of the
skin and gastrointestinal tract, but may be present in the vaginal tract of 20
to 30% of asymptomatic healthy women at any given time. If the balance between
the colonizing yeast and the host is temporarily disrupted, Candida can cause
infections such as vaginal candidiasis, associated with clinical signs of
inflammation (Achkar and Fries, 2010). Candida albicans is known to be
resistant to certain antifungal drugs and is generally treated with azole
antifungals due to their low toxicity and availability (Dovnik et al., 2015;
Whaley et al., 2016).
Vulvovaginal
candidiasis is a public health issue due to the morbidity associated with
symptoms in women (Bitew and Abebaw, 2018). The prevalence varies from one
country to another. In Côte d'Ivoire, some studies in women reported that the
prevalence rate was higher than 28% from non-pregnant women (Djohan et al.,
2012; Konaté et al., 2014). Few studies have focused on vaginal candidiasis in
pregnant women. Therefore, the aim of this study was to determine the
prevalence of vulvovaginal and antifungal susceptibility pattern among pregnant
women at the university teaching hospital of Angré in Abidjan.
Reference
Achkar JM, Fries BC. 2010. Candida Infections
of the Genitourinary Tract. Clinical Microbiology Reviews 23, 253–273.
DOI: 10.1128/CMR.00076-09.
Ahmad A, Khan AU. 2009.
Prevalence of Candida species and potential risk factors for vulvovaginal
candidiasis in Aligarh, India. European Journal of Obstetrics & Gynecology
and Reproductive Biology 144, 68–71. DOI: 10.1016/j.ejogrb.2008.12.020.
Benchellal M, Guelzim
K, Lemkhente Z, Jamili H, Dehainy M, Rahali-Moussaoui D, El Mellouki W, Sbai
Idrissi K, Lmimouni B. 2011. La candidose vulvo-vaginale à l’hôpital
militaire d’instruction Mohammed V (Maroc). Journal de Mycologie Médicale 21,
106–112. DOI: 10.1016/j.mycmed.2011.03.003.
Bender RA, Calışkan S,
Önal B, Aslancan R, Caliskan E. 2021. Treatment methods for vulvovaginal
candidiasis in pregnancy. Journal de Mycologie Médicale 31, 101138. DOI:
10.1016/j.mycmed.2021.101138.
Bitew A, Abebaw Y. 2018.
Vulvovaginal candidiasis: species distribution of Candida and their
antifungal susceptibility pattern. BMC Women’s Health 18, 94. DOI:
10.1186/s12905-018-0607-z.
Blomberg L, Backman K,
Kirjavainen PV, Karvonen AM, Harju M, Keski-Nisula L. 2023. Vulvovaginal
yeast infections, gestational diabetes and pregnancy outcome. BMC pregnancy and
childbirth 23, 70. DOI: 10.1186/s12884-023-05391-1.
Clinical Laboratory
Standards Institute. 2018. Reference method for broth dilution Antifungal
susceptibility testing of yeasts; approved Standard CLSI Document M27-A3.
Djohan V, Angora KE,
Vanga-Bosson AH, Konaté A, Kassi FK, Yavo W, Kiki-Barro PC, Menan H, Koné M. 2012.
Sensibilité in vitro des souches de Candida albicans d’origine
vaginale aux antifongiques à Abidjan (Côte d’Ivoire). Journal de Mycologie
Médicale 22, 129–133. DOI: 10.1016/j.mycmed.2011.11.005.
Dovnik A, Golle A,
Novak D, Arko D, Takac I. 2015. Treatment of vulvovaginal candidiasis: a
review of the literature. Acta Dermatovenerologica Alpina, Pannonica, Et
Adriatica 24, 5–7. DOI: 10.15570/actaapa.2015.2.
Duarte G, Linhares IM,
Kreitchmann R, Tristao A, Da R, Traina E, Canti I, Takimura M, Andrade
JQ. 2024. Vulvovaginitis in pregnant women. Revista Brasileira De
Ginecologia E Obstetricia 46, e-FPS03. DOI: 10.61622/rbgo/2024FPS03.
Ekwealor CC, Okoro EO,
Oyeka CA, Amasiani R. 2023. Vaginal Candidiasis among Pregnant Women in
Ebonyi State, South East Nigeria. The Bioscientist Journal 11, 220–230.
Fanou BA, Klotoe JR,
Dougnon V, Monteiro A, Koudokpon CH, Loko F. 2022. Prévalence et facteurs
associés aux candidoses vulvovaginales chez les femmes admises en consultation
à l’Hôpital de Zone de Mènontin (Bénin). The Pan African Medical Journal 42,
215. DOI: 10.11604/pamj.2022.42.215.28984.
Gai S, Wu Q, Zhang H. 2023.
The change of inflammatory status and vaginal flora in pregnant women with
premature rupture of membranes. Journal of Medical Microbiology 72, 42–47.
DOI: 10.1099/jmm.0.001678.
Gedefie A, Shimeles G,
Motbainor H, Kassanew B, Genet C. 2025. Vaginal colonization and vertical
transmission of Candida species: prevalence and associated factors
among pregnant women and their neonates at public health facilities of
Northeast Ethiopia. BMC Pregnancy and Childbirth 25, 22. DOI:
10.1186/s12884-024-07103-9.
Ghaddar N, Anastasiadis
E, Halimeh R, Ghaddar A, Dhar R, AlFouzan W, Yusef H, El Chaar M. 2020.
Prevalence and antifungal susceptibility of Candida albicans causing
vaginal discharge among pregnant women in Lebanon. BMC infectious
diseases 20, 32. DOI: 10.1186/s12879-019-4736-2.
Hong E, Dixit S, Fidel
PL, Bradford J, Fischer G. 2014. Vulvovaginal Candidiasis as a Chronic
Disease: Diagnostic Criteria and Definition. Journal of Lower Genital Tract
Disease 18, 31–38. DOI: 10.1097/LGT.0b013e318287aced.
Hussen I, Aliyo A,
Abbai MK, Dedecha W. 2024. Vaginal candidiasis prevalence, associated
factors, and antifungal susceptibility patterns among pregnant women attending
antenatal care at bule hora university teaching hospital, Southern Ethiopia.
BMC pregnancy and childbirth 24, 619. DOI: 10.1186/s12884-024-06844-x.
Kechia FA, Dohbit JS, Kouotou
EA, Iwewe, SY, Dzoyem JP, Mbopuwouo NM, Monamele CG, Moyou SR. 2015.
Profil épidémiologique et “tiologique de la Candidose Vulvo-Vaginale chez la
Femme Enceinte à Yaoundé (Cameroun). Health Sciences and Disease 16, 6.
DOI: 10.5281/hsd.v16i4.594.
Konadu DG, Owusu-Ofori
A, Yidana Z, Boadu F, Iddrisu LF, Adu-Gyasi D, Dosoo D, Awuley RL, Owusu-Agyei
S, Asante KP. 2019. Prevalence of vulvovaginal candidiasis, bacterial
vaginosis and trichomoniasis in pregnant women attending antenatal clinic in
the middle belt of Ghana. BMC Pregnancy and Childbirth 19, 341. DOI:
10.1186/s12884-019-2488-z.
Konaté A, Yavo W, Kassi
FK, Djohan V, Angora EK, Barro-Kiki PC, Bosson-Vanga H, Soro F, Menan EIH. 2014.
Aetiologies and contributing factors of vulvovaginal candidiasis in Abidjan
(Cote d’Ivoire). Journal de Mycologie Médicale 24, 93–99. DOI:
10.1016/j.mycmed.2013.11.006.
Konaté-Touré A,
Fulgence KK, Paterne AG., Estelle GK, Valérie A B-T, Henriette V-B, Etienne K
A, Sebastien AM, Vincent D, Kiki-Barro PC, Hervé EM, William Y. 2024.
Etiology and Risk Factors in Patients with Vulvovaginal Candidiasis in Abidjan
(Côte d’Ivoire). Journal of Mycology and Infection 29, 155–164. DOI:
10.17966/JMI.2024.29.3.155.
Kone AK, Timbine LG,
Diallo MH, Niare-Doumbo S, Soumare I, Ranque S, Kouriba B, Thera MA. 2025. In
Vitro Susceptibility of Candida spp. Isolates to Antifungals
from Patients at Charles Mérieux Infectious Disease Centre (CICM) in Bamako,
Mali. African Journal of Parasitology Mycology and Entomology 3, 1–14.
DOI: 10.35995/ajpme03010001.
Maftei NM, Arbune M,
Georgescu CV, Elisei AM, Iancu AV, Tatu AL. 2023. Vulvovaginal Candidiasis
in Pregnancy-Between Sensitivity and Resistance to Antimycotics. Journal of
Xenobiotics 13, 312–322. DOI: 10.3390/jox13030023.
Nelson MC, Wanyoike W,
Margaret MW. 2013. Prevalence of Vaginal Candidiasis and Determination of
the Occurrence of Candida Species in Pregnant Women Attending the
Antenatal Clinic of Thika District Hospital, Kenya. Open Journal of Medical
Microbiology 03, 4–8. DOI: 10.4236/ojmm.2013.34040.
Ogouyèmi-Hounto A,
Adisso S, Djamal J, Sanni R, Amangbegnon R, Biokou-Bankole B, Kinde Gazard D,
Massougbodji A. 2014. Place des candidoses vulvo-vaginales au cours des
infections génitales basses et facteurs de risque associés chez les femmes au
Bénin. Journal de Mycologie Médicale 24, 100–105. DOI:
10.1016/j.mycmed.2014.01.003.
Osman-Mohamed A,
Suliman MM, Hussain MT, Abdelrahman HM, Ali JM, Ali OK, Omar AM, Makki Mohamed
AA. 2022. Prevalence of vulvovaginal candidiasis among pregnant women in
Africa: A systematic review and meta-analysis. Journal of Infection in
Developing Countries 16, 1243–1251. DOI: 10.3855/jidc.15536.
Rodrigo PD, Georgina R,
Érica LS, Luciano T, Josefina JM. 2024. Candida species isolated
in female patients of reproductive age with vaginal candidiasis in
Gualeguaychú, Entre Ríos, Argentina. Journal of Bacteriology & Mycology:
Open Access 12, 98–101. DOI: 10.15406/jbmoa.2024.12.00381.
Roy M, Majumdar T, Ray
J. 2024. Vulvovaginal candidiasis in pregnant women attending a tertiary
care centre in North-Eastern India. Indian Journal of Medical
Microbiology 52, 100738. DOI: 10.1016/j.ijmmb.2024.100738.
Satora M, Grunwald A,
Zaremba B, Frankowska K, Zak K, Tarkowski R, Kutak K. 2023. Treatment of
Vulvovaginal Candidiasis-An Overview of Guidelines and the Latest Treatment
Methods. Journal of Clinical Medicine 12, 5376. DOI: 10.3390/jcm12165376.
Sobel JD. 2007.
Vulvovaginal candidosis. Lancet 369, 1961–1971. DOI: 10.1016/S0140-6736(07)60917-9.
Sule-Odu AO, Akadri AA,
Oluwole AA, Osinupebi OA, Andu BA, Akiseku AK, Lawal AI. 2020.
Vaginal Candida infection in pregnancy and its implications for fetal
well-being. African Journal of Reproductive Health 24, 33–40. DOI:
10.29063/ajrh2020/v24i3.4.
Sy O, Diongue K, Ahmed
CB, Ba O, Moulay FC, Lo B, Ndiaye D. 2018. Vulvovaginal candidiasis in
pregnant women in the Mère et Enfant Hospital center in Nouakchott, Mauritania.
Journal de Mycologie Médicale 28, 345–348. DOI: 10.1016/j.mycmed.2018.02.006.
Waikhom SD, Afeke I,
Kwawu GS, Mbroh HK, Osei GY, Louis B, Deku JG, Kasu ES, Mensah P, Agede CY,
Dodoo C, Asiamah EA, Tampuori J, Korbuvi J, Opintan JA. 2020. Prevalence
of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana:
species identification and antifungal susceptibility of Candida isolates.
BMC pregnancy and childbirth 20, 266. DOI: 10.1186/s12884-020-02963-3.
Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. 2016. Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Frontiers in Microbiology 7, 2173. DOI: 10.3389/fmicb.2016.02173.
Article source : Vulvovaginal candidiasis and antifungal susceptibility patterns among pregnant women at the university hospital of Angré, Abidjan, Côte d’Ivoire












